Researchers at Johns Hopkins University have identified an agent that may improve the quality of life for ALS patients by limiting muscle atrophy. They found that injecting the agent (a soluble protein called ACE031) resulted in ALS mice whose muscles remained larger and stronger than those not treated with the agent. While ACE031 does not impact the loss of motor neurons, it seems to enable existing motor neurons to innervate bigger and stronger muscles. Acceleron has begun testing the agent in phase I trials in healthy humans.
Click here to read more.Share this: